Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBIT Margin (2017 - 2025)

Organogenesis Holdings has reported EBIT Margin over the past 9 years, most recently at 28.05% for Q4 2025.

  • Quarterly results put EBIT Margin at 28.05% for Q4 2025, up 1998.0% from a year ago — trailing twelve months through Dec 2025 was 7.92% (up 819.0% YoY), and the annual figure for FY2025 was 7.92%, up 819.0%.
  • EBIT Margin for Q4 2025 was 28.05% at Organogenesis Holdings, up from 13.74% in the prior quarter.
  • Over the last five years, EBIT Margin for ORGO hit a ceiling of 28.05% in Q4 2025 and a floor of 30.85% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 7.48% (2023), compared with a mean of 4.43%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 3674bps in 2021 and later crashed -2735bps in 2025.
  • Organogenesis Holdings' EBIT Margin stood at 15.45% in 2021, then crashed by -51bps to 7.55% in 2022, then plummeted by -117bps to 1.27% in 2023, then skyrocketed by 734bps to 8.07% in 2024, then soared by 248bps to 28.05% in 2025.
  • The last three reported values for EBIT Margin were 28.05% (Q4 2025), 13.74% (Q3 2025), and 12.45% (Q2 2025) per Business Quant data.